Martinez Perez-Crespo, P MLopez Cortes, L E2025-01-072025-01-072021-09-30Martínez Pérez-Crespo PM, López Cortés LE. Ceftobiprole: a clinical view. Rev Esp Quimioter. 2021 Sep;34 Suppl 1(Suppl1):32-34.https://hdl.handle.net/10668/27300Ceftobiprole is a broad-spectrum, fifth-generation cephalosporin currently approved for community-acquired and non-ventilator-associated hospital-acquired pneumonia. High bactericidal and anti-biofilm activity has been exhibited in in vitro and animal models. This, together with its synergism with other antibiotics against gram-positive bacteria, makes it an ideal candidate for treatment of complex infections, such as those associated with devices or infective endocarditis. More clinical data are needed to achieve drug positioning.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/ceftobiproleMRSAsynergyanti-biofilmAnimalsAnti-Bacterial AgentsCephalosporinsEndocarditis, BacterialGram-Positive BacteriaAnimalsCephalosporinsMonobactamsEndocarditisGram-Positive BacteriaModels, AnimalPneumoniaHospitalsresearch article34598421open accessAntibacterianosTécnicas In VitroPreparaciones farmacéuticasBiopelículasHospitalesBacterias grampositivasCefalosporinasNeumoníaCaracterísticas de la residenciaVentiladores mecánicosTerapéuticaInfeccionesEndocarditis10.37201/req/s01.09.20211988-9518PMC8683001https://seq.es/wp-content/uploads/2021/10/09.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8683001/pdf